Sepsis News and Research

Latest Sepsis News and Research

Study shows how fish oils help lower blood pressure via vasodilation at ion channels

Omega-3 fatty acids found in oily fish may have diverse health-promoting effects, potentially protecting the immune, nervous, and cardiovascular systems.

6 Mar 2013

Accenture supports Unified Clinical Organization to improve care coordination, patient outcomes

The Unified Clinical Organization, an innovative care improvement model from Trinity Health, is improving care coordination, patient outcomes and advancing standardization of care practices with support from Accenture.

6 Mar 2013

Researchers identify mechanisms that connect variety of diseases linked with inflammation

A study led by researchers at Boston University School of Medicine (BUSM) has identified epigenetic mechanisms that connect a variety of diseases associated with inflammation.

3 Mar 2013

Cubist receives FDA QIDP designation for ceftolozane/tazobactam to treat HABP/ VABP, cUTI

Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated the company's late-stage antibiotic candidate, ceftolozane/tazobactam, as a Qualified Infectious Disease Product (QIDP) for the indications of Hospital-Acquired Bacterial Pneumonia (HABP)/Ventilator-Associated Bacterial Pneumonia (VABP) and Complicated Urinary Tract Infections (cUTI).

1 Mar 2013

One in three ventilated people with ALI shows substantial PTSD symptoms

One in three people who survived stays in an intensive care unit (ICU) and required use of a mechanical ventilator showed substantial post-traumatic stress disorder (PTSD) symptoms that lasted for up to two years, according to a new Johns Hopkins study of patients with acute lung injury.

26 Feb 2013

Xellia to develop new antibiotics effective against multi-drug resistant Gram-negative bacteria

Xellia Pharmaceuticals, a fully integrated specialty pharmaceutical company focusing on the global anti-infective market, announced today that it is developing new antibiotics effective against multi-drug resistant (MDR), Gram-negative bacteria.

26 Feb 2013

Thermo Fisher Scientific launches Brilliance GBS Agar

Thermo Fisher Scientific Inc., the world leader in serving science, today announced the launch of Brilliance GBS Agar for the testing of Group B streptococci (GBS) during pregnancy.

From Thermo Fisher Scientific Inc. 26 Feb 2013

Scientists uncover atomic structure of dermcidin

An international team of scientists has discovered how an important natural antibiotic called dermcidin, produced by our skin when we sweat, is a highly efficient tool to fight tuberculosis germs and other dangerous bugs.

22 Feb 2013

FDA approves new vial size for CSL Behring’s Privigen to treat primary immunodeficiency

CSL Behring today announced that the United States Food and Drug Administration has approved a 40 g (400 mL) vial size for Privigen, immune globulin intravenous [human].

21 Feb 2013

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

UCB announced today two new regulatory filings with the US Food and Drug Administration (FDA) and with the European Medicines Agency (EMA) to extend the marketing authorization for Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA) and for adult patients with active axial spondyloarthritis (axSpA).

20 Feb 2013

Risk factors for invasive candidiasis in infants clarified

A combination of exposure to broad-spectrum antibiotics and having a platelet count below 50,000/mm3 significantly increases a low-to-normal–weight infant’s chance for developing invasive candidiasis, report researchers.

19 Feb 2013

Combining synthetic and natural toxins could disarm cancer, drug-resistant bacteria

Cancer researchers from Rice University suggest that a new man-made drug that's already proven effective at killing cancer and drug-resistant bacteria could best deliver its knockout blow when used in combination with drugs made from naturally occurring toxins.

13 Feb 2013

Symposium to discuss new techniques for assessing risk of acute kidney injury

Leading critical care experts will discuss new techniques for assessing risk of acute kidney injury (AKI) at an educational symposium to be held at the Eighteenth International Conference on Continuous Renal Replacement Therapies (CRRT) in San Diego.

11 Feb 2013

Celgene receives FDA approval for POMALYST to treat multiple myeloma

Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved POMALYST brand therapy (pomalidomide) for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.

10 Feb 2013

Feeding human breast milk to very-low-birth-weight infants reduces risk of sepsis and NICU costs

Feeding human breast milk to very-low-birth-weight infants greatly reduces risk for sepsis and significantly lowers associated neonatal intensive care unit (NICU) costs, according to a study by Rush University Medical Center researchers.

6 Feb 2013

Caution on COX inhibitor use in preterm infants

Very-low-birthweight preterm infants with thrombocytopenia treated with cyclooxygenase inhibitors are at an increased risk for intracerebral hemorrhage, particularly if they have decreased platelet levels, research shows.

5 Feb 2013

Operative drainage after pancreatic resection ‘should be abandoned’

Routine prophylactic drainage offers no benefits to patients undergoing pancreatic resection, say researchers.

4 Feb 2013

Feinstein Institute, Merck Serono to develop antibodies for treatment of SLE

Merck Serono, a division of Merck, Darmstadt, Germany, and The Feinstein Institute for Medical Research, announced today that they will collaborate to develop antibodies for the treatment of systemic lupus erythematosus (SLE).

30 Jan 2013

Temple scientists to solve long-standing mystery in sepsis

Scientists at the Center for Translational Medicine at the Temple University School of Medicine are inching closer to solving a long-standing mystery in sepsis, a complex and often life-threatening condition that affects more than 400,000 people in the U.S. every year.

28 Jan 2013

FDA approves Takeda’s NESINA, OSENI and KAZANO for treatment of type 2 diabetes

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise.

28 Jan 2013

Sepsis News and Research

Latest Sepsis News and Research

Study shows how fish oils help lower blood pressure via vasodilation at ion channels

Accenture supports Unified Clinical Organization to improve care coordination, patient outcomes

Researchers identify mechanisms that connect variety of diseases linked with inflammation

Cubist receives FDA QIDP designation for ceftolozane/tazobactam to treat HABP/ VABP, cUTI

One in three ventilated people with ALI shows substantial PTSD symptoms

Xellia to develop new antibiotics effective against multi-drug resistant Gram-negative bacteria

Thermo Fisher Scientific launches Brilliance GBS Agar

Scientists uncover atomic structure of dermcidin

FDA approves new vial size for CSL Behring’s Privigen to treat primary immunodeficiency

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

Risk factors for invasive candidiasis in infants clarified

Combining synthetic and natural toxins could disarm cancer, drug-resistant bacteria

Symposium to discuss new techniques for assessing risk of acute kidney injury

Celgene receives FDA approval for POMALYST to treat multiple myeloma

Feeding human breast milk to very-low-birth-weight infants reduces risk of sepsis and NICU costs

Caution on COX inhibitor use in preterm infants

Operative drainage after pancreatic resection ‘should be abandoned’

Feinstein Institute, Merck Serono to develop antibodies for treatment of SLE

Temple scientists to solve long-standing mystery in sepsis

FDA approves Takeda’s NESINA, OSENI and KAZANO for treatment of type 2 diabetes

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Sepsis News and Research

Latest Sepsis News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in